CAPR: FDA Reviews BLA
Capricor Therapeutics announces FDA advisory committee meeting to review BLA for Deramiocel for Duchenne Muscular Dystrophy treatment
CAPR - Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy